Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction (HFPEF)
Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients.
More than half of heart failure patients have preserved ejection fraction (HFpEF), a condition caused by increased wall stiffness that impairs proper heart filling.
- Trial name
- NCT06731738
- Testing
- Gadoteric acid, Mangafodipir trisodium injection
- Where
- Norway
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- IC TARGETS AS
Heart Failure, Heart Failure, Diastolic
A Preliminary Study for INFORMED
Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding…
- Conditions
- Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure
- Trial name
- PRE-INFORMED (NCT05585125)
- Testing
- Beta blocker
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Weill Medical College of Cornell University
Heart Failure With Preserved Ejection Fraction
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
A phase 1, randomized, double-blind, placebo-controlled single-ascending dose study to assess JK07 in adult subjects with heart failure with preserved ejection fraction.
- Trial name
- NCT05322616
- Testing
- JK07
- Where
- 7 sites in United States
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure With Preserved Ejection Fraction
Effects of Sauna on Cardiac and Skeletal Muscle Function in Patients With HFpEF (SAUNA-HFpEF)
Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure where the heart pumps normally but patients still experience symptoms like fatigue, shortness of breath, and reduced ability to exercise.
- Trial name
- SAUNA-HFpEF (NCT06978868)
- Testing
- Sauna Intervention in Clinically Stable Outpatients with HFpEF
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Otto-von-Guericke University Magdeburg
Heart Failure With Preserved Ejection Fraction (HFPEF)
Copenhagen Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure (HF) worldwide, in tandem with ageing of the general population and the increasing prevalence of obesity, diabetes…
- Trial name
- CPH-HFpEF (NCT06685237)
- Where
- Denmark
- Volunteers
- 5,000 people
- Sponsor
- Tor Biering-Sørensen
Heart Failure
Change of NLRP3 Inflammasome Expression Level, Symptoms, and Functional Status in HFpEF Patients Treated With ARNI
Underlying inflammation has been increasingly recognized in heart failure with a preserved ejection fraction(HFpEF). But there is no study reported the relationship between NLRP3 inflammasome and HFpEF.
- Trial name
- NCT04269057
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chongqing Medical University
Heart Failure With Preserved Ejection Fraction
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with…
- Trial name
- ENDEAVOR (NCT04986202)
- Testing
- AZD4831
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 711 people
- Sponsor
- AstraZeneca
Heart Failure With Preserved Ejection Fraction
Clinical Study of Active Intervention in High-risk HFpEF Patients
Based on inclusion and exclusion criteria, this experiment plans to include 924 Heart Failure with Preserved Ejection Fraction(HFpEF) patients with increased risk of all-cause death.
- Trial name
- NCT06532019
- Testing
- Targeted intervention based on risk factors
- Volunteers
- 924 people
- Sponsor
- Xiangtan Central Hospital
Heart Failure, Heart Failure With Preserved Ejection Fraction
EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction
Empagliflozin was recommended for patients with heart failure with reduced ejection fraction (HFrEF) in 2021 European Society of Cardiology (ESC) guidelines (Class of Recommendation Ia) and patients with heart failure with…
- Trial name
- NCT05584319
- Testing
- Empagliflozin 10 Mg
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhijun Sun
Heart Failure With Preserved Ejection Fraction, Obesity
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry
GLIDE-HF is a prospective, single-center, non-interventional observational cohort registry conducted within routine outpatient heart failure care at a cardiology clinic in Poland.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Obesity, Diastolic Heart Failure, Pulmonary Hypertension
- Trial name
- GLIDE-HF (NCT07787936)
- Testing
- GLP-1 / GIP receptor agonist
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Miedziowe Centrum Zdrowia SA
Pacemaker, Diastolic Dysfunction
Personalized Pacing: A New Paradigm for Patients With Diastolic Dysfunction or Heart Failure With Preserved Ejection Fraction
Recent exploratory studies suggest that pacemaker patients with diastolic dysfunction (DD) or heart failure with preserved ejection fraction (HFpEF) may benefit from a higher backup heart rate (HR) setting than the factory…
- Conditions
- Pacemaker, Diastolic Dysfunction, Diastolic Heart Failure
- Trial name
- myPACE (NCT04721314)
- Testing
- Adjustment of lower rate limit, Maintenance of lower rate limit
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- University of Vermont
Heart Failure With Preserved Ejection Fraction
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
- Trial name
- NCT07083011
- Testing
- 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Arterial Hypertension, Atherosclerosis Occlusive Disease
Gut Microbiota in Chronic Noncommunicable Diseases
It is an observational study in patients with chronic noncommunicable diseases (i.e. cardiovascular diseases, diabetes mellitus, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease and asthma ) and control…
- Conditions
- Arterial Hypertension, Atherosclerosis Occlusive Disease, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
- Trial name
- NCT04820556
- Where
- 2 sites in Russia
- Volunteers
- 1,084 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Heart Failure
The HF-POL Study - Multicenter Study of Polish Patients With HF and LVEF >40%
HF-POL is the first Polish multicenter observational prospective registry of patients with heart failure and ejection fraction more than 40% designed by Heart Failure Association of the Polish Cardiac Society.
- Trial name
- HF-POL (NCT06030661)
- Where
- Poland
- Volunteers
- 1,497 people
- Sponsor
- Medical University of Lodz
HFpEF - Heart Failure With Preserved Ejection Fraction
HEART Camp Connect -Promoting Exercise in Adults With Heart Failure With Preserved Ejection Fraction
The goal of this study is to learn more about patients with heart failure with preserved ejection fraction (HFpEF) and exercise.
- Trial name
- NCT05784753
- Testing
- HEART Camp, HEART Camp Connect
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Hypertension, Pulmonary
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH).
- Trial name
- HARMONIZE (NCT06814145)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Belgium and 10 more
- Volunteers
- 440 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
- Trial name
- NCT06616974
- Testing
- TX000045- Dose A, TX000045- Dose B
- Where
- 72 sites in United States, Armenia and 15 more
- Volunteers
- 191 people
- Sponsor
- Tectonic Therapeutic
Heart Failure With Preserved Ejection Fraction
Transitions of Care Clinic (TOCC)
The transition period from hospital to home is a time of heightened risk for patients to experience adverse events, medication errors, and readmission to the hospital.
- Trial name
- NCT06937827
- Testing
- HF Kit and Follow-ups
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Hackensack Meridian Health
Diastolic Heart Failure
High Intensity Interval Exercise in Diastolic Heart Failure
Heart failure is a major health concern and is the leading cause of hospitalization among elderly Americans. Currently 5.7 million Americans are estimated to have heart failure and the estimated direct and indirect costs of…
- Trial name
- NCT02147613
- Testing
- High intensity interval training, Moderate intensity exercise training
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Arizona State University
Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study
This is a prospective single-center cohort study conducted at The First Affiliated Hospital of Xinjiang Medical University, aiming to enroll 400 patients with chronic heart failure (including HFrEF, HFmrEF, HFpEF) and 200 healthy…
- Conditions
- Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Trial name
- HF-MultiOmics (NCT07355088)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Xinjiang Medical University